These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 34991700)

  • 41. Safety and Efficacy of Fidaxomicin and Vancomycin in Children and Adolescents with Clostridioides (Clostridium) difficile Infection: A Phase 3, Multicenter, Randomized, Single-blind Clinical Trial (SUNSHINE).
    Wolf J; Kalocsai K; Fortuny C; Lazar S; Bosis S; Korczowski B; Petit A; Bradford D; Croos-Dabrera R; Incera E; Melis J; van Maanen R
    Clin Infect Dis; 2020 Dec; 71(10):2581-2588. PubMed ID: 31773143
    [TBL] [Abstract][Full Text] [Related]  

  • 42. In vitro susceptibility of Clostridium difficile to rifaximin and rifampin in 359 consecutive isolates at a university hospital in Houston, Texas.
    Jiang ZD; DuPont HL; La Rocco M; Garey KW
    J Clin Pathol; 2010 Apr; 63(4):355-8. PubMed ID: 20354207
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Fidaxomicin: a macrocyclic antibiotic for the management of Clostridium difficile infection.
    Sullivan KM; Spooner LM
    Ann Pharmacother; 2010 Feb; 44(2):352-9. PubMed ID: 20071495
    [TBL] [Abstract][Full Text] [Related]  

  • 44. U.S.-Based National Sentinel Surveillance Study for the Epidemiology of Clostridium difficile-Associated Diarrheal Isolates and Their Susceptibility to Fidaxomicin.
    Snydman DR; McDermott LA; Jacobus NV; Thorpe C; Stone S; Jenkins SG; Goldstein EJ; Patel R; Forbes BA; Mirrett S; Johnson S; Gerding DN
    Antimicrob Agents Chemother; 2015 Oct; 59(10):6437-43. PubMed ID: 26239985
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Fidaxomicin: in Clostridium difficile infection.
    Duggan ST
    Drugs; 2011 Dec; 71(18):2445-56. PubMed ID: 22141387
    [TBL] [Abstract][Full Text] [Related]  

  • 46. RstA Is a Major Regulator of Clostridioides difficile Toxin Production and Motility.
    Edwards AN; Anjuwon-Foster BR; McBride SM
    mBio; 2019 Mar; 10(2):. PubMed ID: 30862746
    [No Abstract]   [Full Text] [Related]  

  • 47. Characterization of Flagellum and Toxin Phase Variation in Clostridioides difficile Ribotype 012 Isolates.
    Anjuwon-Foster BR; Maldonado-Vazquez N; Tamayo R
    J Bacteriol; 2018 Jul; 200(14):. PubMed ID: 29735765
    [No Abstract]   [Full Text] [Related]  

  • 48. Fidaxomicin: a novel macrocyclic antibiotic for the treatment of Clostridium difficile infection.
    Crawford T; Huesgen E; Danziger L
    Am J Health Syst Pharm; 2012 Jun; 69(11):933-43. PubMed ID: 22610025
    [TBL] [Abstract][Full Text] [Related]  

  • 49. European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults.
    van Prehn J; Reigadas E; Vogelzang EH; Bouza E; Hristea A; Guery B; Krutova M; Norén T; Allerberger F; Coia JE; Goorhuis A; van Rossen TM; Ooijevaar RE; Burns K; Scharvik Olesen BR; Tschudin-Sutter S; Wilcox MH; Vehreschild MJGT; Fitzpatrick F; Kuijper EJ;
    Clin Microbiol Infect; 2021 Dec; 27 Suppl 2():S1-S21. PubMed ID: 34678515
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antimicrobial Susceptibilities of Clostridium difficile Isolates from 12 Asia-Pacific Countries in 2014 and 2015.
    Lew T; Putsathit P; Sohn KM; Wu Y; Ouchi K; Ishii Y; Tateda K; Riley TV; Collins DA
    Antimicrob Agents Chemother; 2020 Jun; 64(7):. PubMed ID: 32393487
    [No Abstract]   [Full Text] [Related]  

  • 51. Investigations of the mode of action and resistance development of cadazolid, a new antibiotic for treatment of Clostridium difficile infections.
    Locher HH; Caspers P; Bruyère T; Schroeder S; Pfaff P; Knezevic A; Keck W; Ritz D
    Antimicrob Agents Chemother; 2014; 58(2):901-8. PubMed ID: 24277035
    [TBL] [Abstract][Full Text] [Related]  

  • 52. High Prevalence of Multidrug-Resistant
    Mutai WC; Mureithi MW; Anzala O; Revathi G; Kullin B; Burugu M; Kyany'a C; Odoyo E; Otieno P; Musila L
    Front Cell Infect Microbiol; 2020; 10():604986. PubMed ID: 33628744
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Fidaxomicin versus metronidazole, vancomycin and their combination for initial episode, first recurrence and severe Clostridioides difficile infection - An observational cohort study.
    Polivkova S; Krutova M; Capek V; Sykorova B; Benes J
    Int J Infect Dis; 2021 Feb; 103():226-233. PubMed ID: 33188906
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Subinhibitory concentrations of LFF571 reduce toxin production by Clostridium difficile.
    Sachdeva M; Leeds JA
    Antimicrob Agents Chemother; 2015 Feb; 59(2):1252-7. PubMed ID: 25512411
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Fidaxomicin for the treatment of Clostridium difficile infections.
    Whitman CB; Czosnowski QA
    Ann Pharmacother; 2012 Feb; 46(2):219-28. PubMed ID: 22318930
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Fidaxomicin versus vancomycin for Clostridium difficile infection.
    Louie TJ; Miller MA; Mullane KM; Weiss K; Lentnek A; Golan Y; Gorbach S; Sears P; Shue YK;
    N Engl J Med; 2011 Feb; 364(5):422-31. PubMed ID: 21288078
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Temporal Variations in Patterns of
    Wongkuna S; Janvilisri T; Phanchana M; Harnvoravongchai P; Aroonnual A; Aimjongjun S; Malaisri N; Chankhamhaengdecha S
    Antibiotics (Basel); 2021 Jun; 10(6):. PubMed ID: 34199301
    [No Abstract]   [Full Text] [Related]  

  • 58.
    Begum K; Bassères E; Miranda J; Lancaster C; Gonzales-Luna AJ; Carlson TJ; Rashid T; Eyre DW; Wilcox MH; Alam MJ; Garey KW
    Antimicrob Agents Chemother; 2020 Jul; 64(8):. PubMed ID: 32513796
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Fidaxomicin for the Treatment of Clostridium Difficile Infection in the Pediatric Population - Not Quite So Soon Yet.
    Daniels T; So TY
    Gastroenterology Res; 2011 Jun; 4(3):93-96. PubMed ID: 27942322
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Human intestinal enteroids as a model of
    Engevik MA; Danhof HA; Chang-Graham AL; Spinler JK; Engevik KA; Herrmann B; Endres BT; Garey KW; Hyser JM; Britton RA; Versalovic J
    Am J Physiol Gastrointest Liver Physiol; 2020 May; 318(5):G870-G888. PubMed ID: 32223302
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.